Drug or treatment

Cyclophosphamide clinical trials

• 119Clinical trials
• 2New in 30 days
• 30Countries

Newest trials

All recruiting trials (119)

• Polatuzumab Vedotin plus Rituximab with Reduced-dose chemo for frail seniors with DLBCL

  This trial tests whether a gentler, first-line treatment (Polatuzumab Vedotin with Rituximab and reduced-dose chemo) helps older, frail patients with DLBCL stay disease-free longer.

  Recruiting Phase 4 The First Hospital of Jilin University · Changchun, Jilin · NCT07908888

• Chemotherapy sensitivity-guided Culmerciclib combo for HR+/HER2- breast cancer before surgery

  This trial tests whether adding Culmerciclib to chemotherapy before surgery can help people with HR+/HER2- breast cancer who don’t respond to initial TAC treatment.

  Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07900516

• Orelabrutinib plus Pola-R-CHP as first-line treatment for intermediate- to high-risk DLBCL

  This trial tests whether adding orelabrutinib to the Pola-R-CHP regimen can improve outcomes for adults with intermediate- to high-risk newly diagnosed DLBCL.

  Recruiting at 2 sites The First Affiliated Hospital of Xiamen University · Xiamen, Fujian and 1 other locations · NCT07778212

• Can older adults with breast cancer tolerate a dense CMF chemo schedule

  This study tests whether giving a condensed CMF chemotherapy regimen is feasible for people 70 and older with breast cancer.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07768436

• Lower Dose Cyclophosphamide After Haploidentical Stem Cell Transplant

  This trial tests whether giving half the usual amount of cyclophosphamide after haploidentical stem cell transplantation can still prevent GVHD in adults with blood cancers.

  Recruiting Phase 2 Tata Memorial Centre · Navi Mumbai, Maharashtra and 1 other locations · NCT07719946

• Auricular Point Stimulation With Dexamethasone vs Standard Anti-nausea Medications for Docetaxel‑Cyclophosphamide Therapy

  This study tests whether adding ear acupuncture-like stimulation to dexamethasone can match or be as effective as standard antiemetic drugs for preventing nausea and vomiting in people receiving the docetaxel–cyclophosphamide chemotherapy.

  Recruiting Phase 3 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou · NCT07716176

• Post transplant cyclophosphamide, bortezomib, and sitagliptin to prevent graft-versus-host disease after allogeneic transplantation

  This study tests whether a combination of post-transplant cyclophosphamide, bortezomib, and sitagliptin can prevent GvHD in adults undergoing reduced-intensity allogeneic stem cell transplantation from matched related or unrelated donors.

  Recruiting Phase 1/2 Northwell Health · New Hyde Park, New York · NCT07675174

• KCD Regimen for Newly Diagnosed POEMS Syndrome

  The study tests whether the KCD regimen (carfilzomib, cyclophosphamide, and dexamethasone) is safe and effective in adults newly diagnosed with POEMS syndrome.

  Recruiting Phase 2 Shanghai Changzheng Hospital · Shanghai · NCT07652879

• Pyrotinib plus trastuzumab and chemotherapy for HER2-positive early breast cancer

  This study tests a treatment combination of Pyrotinib, Trastuzumab and chemo given before surgery to see if it can improve responses in HER2-positive breast cancer patients who have not yet been treated.

  Recruiting Phase 2 Hebei Medical University Fourth Hospital · Shijiazhuang, Hebei · NCT07635342

• EGFR/HER2 dual-target CAR-NK cells for recurrent or metastatic HNSCC

  This trial tests an allogeneic CAR-NK cell therapy that targets EGFR and HER2 in adults with recurrent or metastatic head and neck cancer that express both biomarkers.

  Recruiting Phase 1/2 Beijing Biotech · Shenzhen, Guangdong · NCT07617805

• Polatuzumab vedotin with Zanubrutinib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone in untreated DLBCL (MCD/BN2/N1)

  This study tests a targeted combination therapy to see if it can treat previously untreated DLBCL with specific molecular subtypes.

  Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07608978

• Bendamustine vs standard lymphodepletion before CAR-T in LBCL

  This trial tests whether bendamustine can replace the standard bendamustine-free lymphodepletion before CAR-T therapy in adults with large B-cell lymphoma who have had prior treatment.

  Recruiting at 8 sites Phase 2 Swiss Cancer Institute · Aarau and 8 other locations · NCT07593482

• Thiotepa-based Conditioning With Reduced Post-Transplant Cyclophosphamide for Allogeneic Stem Cell Transplant in High-Risk Blood C cancers

  This phase 1 trial tests a Thiotepa, Busulfan, and Fludarabine conditioning regimen with de-escalated post-transplant cyclophosphamide to see if it can improve outcomes after allogeneic stem cell transplantation for high-risk blood cancers.

  Recruiting Phase 1 University of Pittsburgh · Pittsburgh, Pennsylvania · NCT07565220

• Dual-target CAR-NK therapy against CLDN18.2 and HER2 for advanced stomach/GEJ cancer

  This trial will test an off-the-shelf, cord-blood-derived CAR-NK cell therapy that targets CLDN18.2 and HER2 in adults with unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma who have progressed after at least two prior treatments.

  Recruiting Phase 1/2 Beijing Biotech · Shenzhen, Guangdong · NCT07551362

• Ear acupressure plus dexamethasone to prevent chemo nausea from docetaxel and cyclophosphamide

  This trial will test whether ear acupressure (auricular point stimulation) combined with dexamethasone can prevent or reduce nausea and vomiting in adults receiving docetaxel plus cyclophosphamide after breast cancer surgery.

  Recruiting Phase 2 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou · NCT07537699

• Dual-target Nectin-4 and HER2 CAR-NK therapy for advanced urothelial carcinoma

  This treatment will try dual-target CAR-NK cells that recognize Nectin‑4 and HER2 in adults with relapsed or metastatic urothelial carcinoma after standard therapies.

  Recruiting Phase 1 Beijing Biotech · Shenzhen, Guangdong · NCT07492628

• Higher-dose chemo over a shorter time vs lower-dose chemo with maintenance in newly diagnosed intermediate-risk rhabdomyosarcoma

  We’re testing whether a shorter, higher-dose chemo plan works better than a longer, maintenance chemo plan for kids and young people with intermediate-risk rhabdomyosarcoma.

  Recruiting at 85 sites Phase 3 Children's Oncology Group · Birmingham, Alabama and 86 other locations · NCT07466316

• Elranatamab plus cyclophosphamide for relapsed/refractory multiple myeloma with high-risk features

  This will test whether adding cyclophosphamide to elranatamab helps people with relapsed or refractory multiple myeloma who have risk factors that might make elranatamab alone less effective.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07454382

• Iberdomide added to chemoimmunotherapy for relapsed or refractory neuroblastoma

  This study tests whether adding iberdomide to a chemoimmunotherapy regimen helps children and young people with relapsed, refractory, or progressing neuroblastoma.

  Recruiting at 4 sites Phase 1/2 National Cancer Institute (NCI) · Oakland, California and 3 other locations · NCT07437963

• EBNK-001 allogeneic NK cell therapy with low-dose IL-15, with or without pembrolizumab, for advanced solid tumors

  This treatment tests an off-the-shelf NK cell product (EBNK-001) given with low-dose IL-15, either alone or with pembrolizumab, in adults with advanced or metastatic solid tumors who have exhausted standard options.

  Recruiting Phase 1/2 Essen Biotech · Beijing, Beijing Municipality · NCT07410676

• SCTC21C plus bortezomib, cyclophosphamide and dexamethasone for newly diagnosed systemic light-chain (AL) amyloidosis

  This trial tests whether adding SCTC21C to standard bortezomib‑cyclophosphamide‑dexamethasone (VCd) helps people with newly diagnosed AL (light‑chain) amyloidosis achieve better hematologic responses and outcomes.

  Recruiting Phase 3 Sinocelltech Ltd. · Beijing, Beijing Municipality · NCT07388602

• VIC-1911 with PTCy and sirolimus to prevent GVHD after haploidentical stem cell transplant in children

  This early-phase trial tests whether adding VIC-1911 to a standard GVHD prevention regimen can help children tolerate and benefit after a haploidentical stem cell transplant.

  Recruiting Phase 1 Shanghai Jiao Tong University School of Medicine · Shanghai, Shanghai Municipality · NCT07350057

• Low-dose post-transplant cyclophosphamide plus tacrolimus and ruxolitinib to prevent GVHD after myeloablative peripheral blood stem cell transplant

  This test sees if adding low-dose post-transplant cyclophosphamide with tacrolimus and ruxolitinib can reduce severe acute graft-versus-host disease in adults receiving myeloablative peripheral blood stem cell transplants for leukemia or myelodysplasia.

  Recruiting at 3 sites Phase 2 Ohio State University Comprehensive Cancer Center · Birmingham, Alabama and 2 other locations · NCT07249346

• Optimizing post-transplant bendamustine plus cyclophosphamide for high‑risk myeloid cancers with a partially mismatched donor

  This trial tests whether giving bendamustine plus cyclophosphamide after transplant (with possible abatacept or ruxolitinib) can reduce dangerous cytokine release and graft‑versus‑host disease for people with high‑risk myeloid malignancies who have a partially HLA‑mismatched donor.

  Recruiting Phase 2 St. Petersburg State Pavlov Medical University · Saint Petersburg · NCT07238712

• Belantamab Mafodotin with a chemotherapy combo for newly diagnosed AL amyloidosis

  This study tests whether adding belantamab mafodotin to a regimen of cyclophosphamide, bortezomib, and dexamethasone can help adults with newly diagnosed AL amyloidosis.

  Recruiting at 16 sites Phase 2 GlaxoSmithKline · Los Angeles, California and 15 other locations · NCT07224672

• Fludarabine with intermediate-dose total body irradiation and PTCy for adults having allogeneic stem cell transplant

  This trial will test whether fludarabine plus intermediate-dose total body irradiation followed by post-transplant cyclophosphamide improves one-year survival for adults (18–65) receiving allogeneic stem cell transplants for blood cancers.

  Recruiting Phase 2 Hackensack Meridian Health · Washington D.C., District of Columbia and 2 other locations · NCT07214688

• Linperlisib plus CPT (cyclophosphamide, prednisone, thalidomide) for relapsed or refractory non-Hodgkin lymphoma

  This trial tests whether adding linperlisib to a CPT regimen helps adults with relapsed or refractory non-Hodgkin lymphoma.

  Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07195799

• Combining donor-derived anti-CD19 CAR-T cells with haploidentical transplant using post-transplant cyclophosphamide

  This trial tests whether giving donor-derived anti-CD19 CAR-T cells together with a haploidentical bone marrow transplant using post-transplant cyclophosphamide can help adults (18–75) with high‑risk CD19+ blood cancers.

  Recruiting Phase 1 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07162038

• Anti-PD-1/PD-L1 with bevacizumab and low-dose cyclophosphamide for metastatic NSCLC and cutaneous melanoma after prior checkpoint therapy

  We will try giving anti-PD-1/PD-L1 drugs together with bevacizumab and continuous low-dose cyclophosphamide to people with metastatic NSCLC or cutaneous melanoma whose cancer progressed after prior immune checkpoint treatment.

  Recruiting Phase 2 EuroCityClinic LLC · Saint Petersburg, Sankt-Peterburg · NCT07130032

• Epcoritamab plus dose‑adjusted EPOCH‑R for aggressive B‑cell lymphoma

  This trial tests whether adding epcoritamab to dose‑adjusted EPOCH‑R chemotherapy can safely improve outcomes for adults with untreated aggressive B‑cell non‑Hodgkin lymphoma.

  Recruiting Phase 2 University of Washington · Seattle, Washington · NCT07097363

• Daratumumab-hyaluronidase added to your myeloma treatment to see if it helps kidney function

  This trial tests whether adding daratumumab-hyaluronidase to the standard bortezomib and dexamethasone therapy improves kidney function in adults newly diagnosed with multiple myeloma and kidney failure.

  Recruiting Phase 2 Eastern Cooperative Oncology Group · Anchorage, Alaska · NCT07085728

• Telitacicept versus cyclophosphamide for lupus-related interstitial lung disease

  This trial will test whether telitacicept works better than cyclophosphamide to treat early interstitial lung disease in adults with lupus.

  Recruiting Phase 4 Tongji Hospital · Wuhan, Hubei · NCT07077486

• BrECADD for stage 2B–III classical Hodgkin lymphoma

  This tests the BrECADD chemotherapy combination in adults 18–60 with stage 2B (with risk factors) or stage III classical Hodgkin lymphoma and uses ctDNA to help track treatment response.

  Recruiting Phase 2 University of Miami · Miami, Florida · NCT07002216

• Adding emapalumab to standard post-transplant medicines to prevent graft‑versus‑host disease after reduced‑intensity donor stem cell transplant

  This trial will test whether adding emapalumab to post‑transplant cyclophosphamide, tacrolimus, and mycophenolate mofetil can prevent graft‑versus‑host disease in adults with AML or MDS receiving a reduced‑intensity donor stem cell transplant.

  Recruiting Phase 1 City of Hope Medical Center · Duarte, California · NCT06996119

• Lower-dose ATG plus mini post‑transplant cyclophosphamide to prevent GVHD after haploidentical stem cell transplant

  This approach tries a lower dose of ATG combined with a short course of post‑transplant cyclophosphamide to prevent graft‑versus‑host disease in people aged 12–65 receiving a haploidentical stem cell transplant for acute leukemia or myelodysplastic syndrome.

  Recruiting Phase 2 Peking University People's Hospital · Beijing · NCT06984536

• Compare two post-transplant drug combinations to prevent graft-versus-host disease

  This phase 2 trial will test whether giving ruxolitinib instead of mycophenolate mofetil, together with cyclophosphamide and sirolimus after a stem cell transplant, better prevents graft-versus-host disease in older adults with AML or related blood cancers.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT06973668

• Allogeneic stem cell transplant with low-dose post-transplant cyclophosphamide to prevent graft-versus-host disease.

  This study tests whether giving low-dose (25 mg/kg) cyclophosphamide on days +3 and +4 after allogeneic peripheral blood stem cell transplant can prevent GVHD in adults with blood cancers who receive reduced-intensity or non-myeloablative conditioning.

  Recruiting Phase 2 Milton S. Hershey Medical Center · Hershey, Pennsylvania · NCT06926595

• Monalizumab treatment for patients with blood cancers undergoing stem cell transplantation

  This study is testing if a new treatment called Monalizumab can help people with blood cancers like AML or MDS who are getting stem cell transplants by improving their immune response and reducing the chances of disease returning or complications.

  Recruiting at 2 sites Phase 2 Istituto Clinico Humanitas · Genova, GENOVA and 1 other locations · NCT06892223

• Post-transplant cyclophosphamide strategies to prevent graft-versus-host disease after mismatched unrelated donor stem cell transplant

  This platform tests whether adding different drug combinations with post-transplant cyclophosphamide prevents graft‑versus‑host disease better than the standard regimen for adults getting mismatched unrelated donor peripheral blood stem cell transplants for blood cancers.

  Recruiting at 13 sites Phase 2 Center for International Blood and Marrow Transplant Research · Birmingham, Alabama and 12 other locations · NCT06859424

• Prostate cryoablation plus low-dose cyclophosphamide with hormonal therapy for metastatic prostate cancer

  This trial will test whether adding prostate cryoablation and continuous low-dose cyclophosphamide to standard hormone therapy with a modern androgen receptor blocker helps men with newly diagnosed metastatic prostate cancer live longer without PSA progression.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT06854250

• Gudinutuximab Beta Added to Standard Chemo for GD2-Positive Ewing Sarcoma (Early-Phase Trial)

  This early-phase study tests whether adding dinutuximab beta to standard VDC/IE chemotherapy is feasible and safe for patients with GD2-positive high-risk Ewing sarcoma.

  Recruiting at 3 sites Phase 1 German Society for Pediatric Oncology and Hematology GPOH gGmbH · Göttingen, Lower Saxony and 4 other locations · NCT06839703

• Vedolizumab with post-transplant cyclophosphamide and short-course tacrolimus to prevent graft-versus-host disease after reduced-intensity allogeneic stem cell transplant

  This trial tests whether adding vedolizumab to post-transplant cyclophosphamide and a short course of tacrolimus can prevent graft-versus-host disease in adults getting reduced-intensity allogeneic stem cell transplants for leukemias or related blood disorders.

  Recruiting Phase 2 City of Hope Medical Center · Duarte, California · NCT06815003

• Intensity-modulated total marrow irradiation for high-risk blood cancers

  This study is testing a new type of radiation treatment combined with standard chemotherapy to see if it helps people with high-risk blood cancers feel better after receiving stem cell transplants.

  Recruiting Phase 2 University of Illinois Chicago · Chicago, Illinois · NCT06802315

• Neoadjuvant treatment for patients with advanced Pseudomyxoma peritonei

  This study is testing a new combination of medications to see if it can help patients with advanced Pseudomyxoma peritonei have better surgery results.

  Recruiting Phase 2 Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Milan · NCT06800391

• Comparing obinutuzumab to cyclophosphamide and glucocorticoids for treating primary membranous nephropathy

  This study is testing if a new drug called obinutuzumab works just as well as the standard treatment of cyclophosphamide and glucocorticoids for people with primary membranous nephropathy.

  Recruiting Phase 3 Huashan Hospital · Shanghai, Shanghai Municipality · NCT06781944

• Combination treatment for advanced triple-negative breast cancer

  This study is testing a new combination of treatments for people with advanced triple-negative breast cancer to see if it helps them feel better and works safely.

  Recruiting at 2 sites Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing, Beijing Municipality and 1 other locations · NCT06771609

• Using Cyclophosphamide and Pembrolizumab for advanced melanoma treatment

  This study is testing if a combination of Cyclophosphamide and Pembrolizumab can help people with advanced melanoma who haven't responded to other treatments feel better and improve their health.

  Recruiting Phase 2 University of California, Irvine · Orange, California · NCT06771544

• Preventing GVHD in children and young adults with blood cancers

  This study is testing a new treatment plan to see if it can help prevent graft-versus-host disease in children and young adults with blood cancers after they receive a transplant.

  Recruiting Phase 2/3 Federal Research Institute of Pediatric Hematology, Oncology and Immunology · Moscow · NCT06756152

• Reduced versus standard dose post-transplant cyclophosphamide with tacrolimus and a single low-dose ATG to prevent GVHD after alternative-donor peripheral stem cell transplant

  This trial will see if a lower dose (35 mg/kg) of post-transplant cyclophosphamide plus tacrolimus and one low dose of ATG prevents graft-versus-host disease as well as the standard 50 mg/kg dose in patients receiving an allogeneic peripheral stem cell transplant from an unrelated or haploidentical donor.

  Recruiting Phase 3 Shanghai Jiao Tong University School of Medicine · Shanghai, Shanghai Municipality · NCT06705062

• Atezolizumab with cyclophosphamide and vinorelbine for metastatic triple-negative breast cancer

  This trial will test whether adding atezolizumab to the chemotherapy drugs cyclophosphamide and vinorelbine helps people with PD-L1–positive metastatic triple-negative breast cancer who are starting first-line treatment after prior PD-1/PD-L1 therapy.

  Recruiting at 2 sites Phase 2 European Institute of Oncology · Monza, Monza and 4 other locations · NCT06690840

• Combination therapy for elderly patients with newly diagnosed diffuse large B-cell lymphoma

  This study is testing a new combination treatment for older patients with newly diagnosed diffuse large B-cell lymphoma who can't tolerate standard chemotherapy to see if it helps them feel better and live longer.

  Recruiting Phase 1/2 Zhengzhou University · Zhengzhou, Henan · NCT06683885

• Bone-marrow stem cell transplant with post-transplant cyclophosphamide for refractory or relapsed severe aplastic anemia in patients over 40

  This trial tests whether bone-marrow allogeneic stem cell transplants using post-transplant cyclophosphamide can lower graft-versus-host disease and improve outcomes in patients aged 40–60 with refractory or relapsing severe aplastic anemia after first-line immunosuppression.

  Recruiting at 19 sites Phase 2 Assistance Publique - Hôpitaux de Paris · Paris, France and 25 other locations · NCT06646497

• Using radiation and chemotherapy before CAR T-cell therapy for multiple myeloma patients with kidney issues

  This study is testing if using low-dose radiation and chemotherapy before CAR T-cell therapy can help people with multiple myeloma and kidney problems get better results.

  Recruiting Phase 1 Washington University School of Medicine · St Louis, Missouri · NCT06623630

• Comparing two treatment regimens for Graft-versus-host Disease after stem cell transplantation

  This study is testing two different treatment plans for adults with Graft-versus-host Disease after stem cell transplantation to see which one works better, especially for those who haven't responded to steroids.

  Recruiting at 30 sites Phase 3 Incyte Corporation · Palo Alto, California and 29 other locations · NCT06615050

• Evaluating R-CMOP treatment for newly diagnosed diffuse large B-cell lymphoma

  This study is testing a new combination treatment for people with newly diagnosed diffuse large B-cell lymphoma to see if it is safe and effective.

  Recruiting Phase 1/2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality · NCT06594640

• Using Sorafenib to Prevent Relapse After Stem Cell Transplantation

  This study is testing if the drug sorafenib can help prevent relapse in patients with high-risk blood cancers after they receive a stem cell transplant.

  Recruiting Phase 2 St. Petersburg State Pavlov Medical University · Saint Petersburg · NCT06532084

• Comparing two regimens for mobilizing stem cells in multiple myeloma patients

  This study is testing whether a new combination of medications can help newly diagnosed multiple myeloma patients collect enough stem cells more effectively than a standard treatment.

  Recruiting at 16 sites Phase 3 The Affiliated People's Hospital of Ningbo University · Dongyang, Zhejiang and 15 other locations · NCT06520176

• Treatment for newly diagnosed monoclonal immunoglobulin deposition disease

  This study is testing a new combination treatment for people who have just been diagnosed with monoclonal immunoglobulin deposition disease to see if it helps improve their blood health.

  Recruiting at 3 sites Phase 2 Peking University People's Hospital · Beijing, Beijing Municipality and 2 other locations · NCT06418477

• Hematopoietic cell transplant for severe blood disorders

  This study is testing a new way to prepare patients with severe blood disorders for a stem cell transplant to see if it can improve their recovery and reduce complications.

  Recruiting Phase 2 Masonic Cancer Center, University of Minnesota · Minneapolis, Minnesota · NCT06412497

• Early immunotherapy for patients with anti-Hu-associated sensory neuronopathy

  This study is testing if early treatment with a combination of medications can help people with anti-Hu-associated sensory neuronopathy feel better after having symptoms for less than three months.

  Recruiting Phase 2 Assistance Publique - Hôpitaux de Paris · Paris · NCT06373211

• Using post-transplant cyclophosphamide and ATG for blood cancer transplants

  This study is testing whether using post-transplant cyclophosphamide and ATG can help prevent graft-versus-host disease in patients with blood cancers who are getting stem cell transplants.

  Recruiting Phase 1/2 Instituto Nacional de Cancer, Brazil · Rio de Janeiro, Rio de Janeiro · NCT06299462

• Testing a new approach to prevent graft-versus-host disease after stem cell transplantation

  This study is testing a new treatment to see if a combination of two drugs can help prevent graft-versus-host disease in patients receiving stem cell transplants, allowing them to stop taking immunosuppressive drugs sooner.

  Recruiting at 3 sites Phase 2 Nantes University Hospital · Angers and 2 other locations · NCT06252870

• Using PTCy and Ruxolitinib to prevent GVHD after stem cell transplants in children with immune disorders

  This study is testing if a new combination of medications can help prevent graft-versus-host disease in children with immune disorders who are getting stem cell transplants.

  Recruiting Phase 2 Federal Research Institute of Pediatric Hematology, Oncology and Immunology · Moscow · NCT06199427

• Low dose treosulfan treatment for Nijmegen Breakage Syndrome

  This study is testing a gentler treatment plan using low dose treosulfan for patients with Nijmegen Breakage Syndrome who are getting a stem cell transplant to see if it helps them have better outcomes with fewer side effects.

  Recruiting Phase 2 Federal Research Institute of Pediatric Hematology, Oncology and Immunology · Moscow · NCT06198842

• Treatment using modified T-cells for relapsed or refractory B-cell cancers

  This study is testing a new treatment that uses specially modified T-cells to see if it can help people with hard-to-treat B-cell cancers.

  Recruiting Phase 1 Mayo Clinic · Jacksonville, Florida · NCT06191887

• Treatment for Richter Syndrome using Glofitamab with Rituximab or Obinutuzumab plus CHOP

  This study is testing if a new treatment combining Glofitamab with Rituximab or Obinutuzumab and CHOP chemotherapy can help people with untreated Richter Syndrome feel better.

  Recruiting at 6 sites Phase 2 French Innovative Leukemia Organisation · Amiens and 22 other locations · NCT06186648

• Induction treatment for newly diagnosed multiple myeloma patients with renal failure

  This study is testing a new treatment plan for people with newly diagnosed multiple myeloma and kidney problems to see if it helps them respond better to therapy.

  Recruiting Early Phase 1 Augusta University · Augusta, Georgia · NCT06142396

• Phase II trial of CMC regimen for early stage breast cancer

  This study is testing a new combination of oral medications for people with early-stage breast cancer to see if it helps them manage their condition safely and effectively.

  Recruiting Phase 2 University of Illinois Chicago · Chicago, Illinois · NCT06085742

• Combining CyBorD with Daratumumab for treating kidney disease related to monoclonal gammopathy

  This study is testing a new treatment combining CyBorD and daratumumab to see if it can help people with kidney disease caused by monoclonal gammopathy feel better and improve their kidney function.

  Recruiting at 8 sites Phase 2 Memorial Sloan Kettering Cancer Center · Boston, Massachusetts and 10 other locations · NCT06083922

• Combining pembrolizumab, bevacizumab, and cyclophosphamide for treating ovarian cancer with minimal residual disease

  This study is testing a new combination of three drugs to see if it can help women with high-grade ovarian cancer who have very little disease left after treatment live longer without their cancer getting worse.

  Recruiting Phase 2 M.D. Anderson Cancer Center · New York, New York and 1 other locations · NCT06083844

• Combining an immunotherapy drug with standard chemotherapy for advanced breast cancer

  This study is testing if adding an immunotherapy drug called durvalumab to standard chemotherapy can help people with advanced hormone receptor-positive, HER2-negative breast cancer live longer and feel better.

  Recruiting at 552 sites Phase 3 National Cancer Institute (NCI) · Birmingham, Alabama and 564 other locations · NCT06058377

• Dose-reduced chemotherapy for older women with early-stage HER2 negative breast cancer

  This study is testing if a lower dose of chemotherapy can help older women with early-stage HER2 negative breast cancer feel better during treatment compared to the standard dose.

  Recruiting at 3 sites Phase 2 City of Hope Medical Center · Duarte, California and 2 other locations · NCT06042569

• Haploidentical stem cell transplantation with early ATG and low-dose cyclophosphamide

  This study is testing if giving a special medication and a lower dose of chemotherapy right after a stem cell transplant can help patients who don't have a matched donor recover better.

  Recruiting Samsung Medical Center · Seoul · NCT06041893

• Comparing chemotherapy with and without stem cell transplant for AL amyloidosis

  This study is testing whether adding a stem cell transplant to chemotherapy can help people with newly diagnosed AL amyloidosis live longer and have better organ health.

  Recruiting at 116 sites Phase 3 SWOG Cancer Research Network · Goodyear, Arizona and 116 other locations · NCT06022939

• Using cord blood transplant and chemotherapy to treat high-risk blood cancers

  This study is testing if combining umbilical cord blood transplants with certain chemotherapy treatments can help people with high-risk blood cancers do better and have fewer side effects.

  Recruiting Phase 2 Fred Hutchinson Cancer Center · Seattle, Washington · NCT06013423

• High-dose Cyclophosphamide treatment for adult patients with Hemophagocytic Syndrome

  This study is testing if high doses of Cyclophosphamide can help adults with Hemophagocytic Syndrome get better and live longer.

  Recruiting The Second Affiliated Hospital of Chongqing Medical University · Chongqing · NCT05936086

• Comparing two chemotherapy regimens for high-risk ER+/HER2- breast cancer

  This study is testing which chemotherapy treatment works better for people with early-stage high-risk breast cancer that is estrogen receptor positive and HER2 negative after surgery.

  Recruiting Phase 3 Fudan University · Shanghai, Shanghai Municipality · NCT05901428

• Using capecitabine and cyclophosphamide for advanced breast cancer maintenance therapy

  This study is testing if a combination of two drugs, capecitabine and cyclophosphamide, can help women with advanced breast cancer stay stable after their previous treatment.

  Recruiting RenJi Hospital · Shanghai · NCT05876065

• Using cyclophosphamide for older patients after stem cell transplant

  This study is testing the best dose of cyclophosphamide for older patients receiving a specific type of stem cell transplant to see how it affects their recovery and health.

  Recruiting Phase 1 Cedars-Sinai Medical Center · Los Angeles, California · NCT05849207

• High-dose immunosuppressive therapy followed by stem cell transplantation for multiple sclerosis

  This study is testing if a high-dose treatment followed by stem cell transplantation can help people with multiple sclerosis who haven't had success with regular treatments.

  Recruiting Phase 1 St. Petersburg State Pavlov Medical University · Saint Petersburg · NCT05832515

• Reduced-intensity treatment followed by stem cell transplant for severe aplastic anemia

  This study is testing a gentler treatment before a stem cell transplant to see if it can safely help people with severe aplastic anemia who haven't responded to other treatments.

  Recruiting Phase 1 City of Hope Medical Center · Duarte, California · NCT05757310

• Evaluating the need for G-CSF in breast cancer patients on chemotherapy

  This study is testing if breast cancer patients on a specific chemotherapy can skip a medication called G-CSF to see if it helps reduce side effects without affecting their treatment success.

  Recruiting at 3 sites Phase 4 Ottawa Hospital Research Institute · Kingston, Ontario and 2 other locations · NCT05753618

• Dasatinib and venetoclax with dexamethasone, cyclophosphamide, and cytarabine for children and young adults with relapsed or refractory ALL/LBL with MAPK/SRC changes

  This treatment tests whether adding dasatinib and venetoclax to dexamethasone, cyclophosphamide, and cytarabine helps children and young people (up to 21) whose relapsed or refractory acute lymphoblastic leukemia or lymphoblastic lymphoma have specific MAPK/SRC pathway changes.

  Recruiting at 2 sites Phase 1/2 Princess Maxima Center for Pediatric Oncology · Vienna and 32 other locations · NCT05751044

• Ruxolitinib and venetoclax added to chemotherapy for children and young adults with relapsed or refractory ALL/LBL

  This trial tests whether adding ruxolitinib and venetoclax to dexamethasone, cyclophosphamide and cytarabine helps children and young adults with relapsed or refractory acute lymphoblastic leukemia or lymphoblastic lymphoma who have IL7R/JAK-STAT pathway changes.

  Recruiting at 3 sites Phase 1/2 Princess Maxima Center for Pediatric Oncology · Vienna and 32 other locations · NCT05745714

• Combination treatment for children with relapsed or refractory blood cancers

  This study is testing a new combination of medications to see if it can help children and young adults with tough-to-treat blood cancers feel better and improve their chances of recovery.

  Recruiting at 5 sites Phase 1/2 Princess Maxima Center for Pediatric Oncology · Vienna and 35 other locations · NCT05658640

• Evaluating the effectiveness of GnRHa for ovarian protection in women with lupus undergoing cyclophosphamide treatment

  This study is testing whether a hormone treatment can help protect the ovaries of women under 40 with lupus who are getting chemotherapy.

  Recruiting National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT05567198

• New treatment approach for HIV patients with blood cancers using bone marrow transplantation

  This study is testing a new combination of drugs to see if it can safely help HIV patients with blood cancers who need a bone marrow transplant, while also preventing complications from the transplant.

  Recruiting Phase 1/2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT05470491

• Combining cyclophosphamide, sorafenib, bevacizumab, and atezolizumab for children and young adults with relapsed solid tumors

  This will test whether giving atezolizumab and bevacizumab every three weeks together with daily cyclophosphamide and dose‑adjusted sorafenib is safe and can shrink relapsed or hard‑to‑treat solid tumors in children and young adults, including fibrolamellar carcinoma.

  Recruiting Phase 1/2 St. Jude Children's Research Hospital · Germantown, Tennessee and 1 other locations · NCT05468359

• Lower dose of cyclophosphamide for preventing complications after blood stem cell transplants

  This study is testing if a lower dose of a medication called cyclophosphamide can help prevent complications after blood stem cell transplants for patients while keeping them safe and healthy.

  Recruiting Phase 1/2 National Institutes of Health Clinical Center (CC) · Duarte, California and 1 other locations · NCT05436418

• Infusing donor lymphocytes after blood cancer transplants to reduce relapse risk

  This study tests if giving special immune cells from a donor to patients with high-risk blood cancers after a transplant can help lower the chance of their cancer coming back.

  Recruiting Phase 1/2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT05327023

• Comparing two treatment regimens for HER-2 positive breast cancer

  This study is testing two different treatment plans for people with HER-2 positive breast cancer to see which one works better before surgery.

  Recruiting Phase 3 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guandong, Guangdong · NCT05159193

• Haploidentical stem cell transplantation for patients with refractory aplastic anemia

  This study tests whether a new type of stem cell transplant from a half-matched donor can help people with severe aplastic anemia who haven't responded to other treatments.

  Recruiting at 35 sites Phase 2 Assistance Publique - Hôpitaux de Paris · Amiens and 34 other locations · NCT05126849

• Combining Ibrutinib and Indoximod for Pediatric Brain Cancer Treatment

  This study is testing a new combination of two drugs, ibrutinib and indoximod, to see if they can safely help children and young adults with hard-to-treat brain tumors feel better.

  Recruiting Phase 1 Augusta University · Augusta, Georgia · NCT05106296

• Reducing cyclophosphamide doses for older or unfit patients undergoing bone marrow transplants

  This study is testing if giving a lower dose of cyclophosphamide can help older or less fit patients with blood cancers have a safer bone marrow transplant by reducing the risk of complications.

  Recruiting at 2 sites Phase 1/2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland and 1 other locations · NCT04959175

• Noninvasive vagal stimulation to help prevent chemotherapy-induced nausea in breast cancer

  This study tests whether a noninvasive vagal nerve stimulation device, used alongside standard anti-nausea medicines, can prevent nausea in breast cancer patients receiving certain chemotherapy drugs.

  Recruiting at 6 sites University Hospital, Tours · Blois and 7 other locations · NCT04937309

• Combination of DPX-Survivac and Pembrolizumab for Relapsed Lymphoma

  This study is testing a new combination treatment of DPX-Survivac and pembrolizumab, with or without a low-dose chemotherapy drug, to see if it helps people with relapsed lymphoma feel better.

  Recruiting at 43 sites Phase 2 ImmunoVaccine Technologies, Inc. (IMV Inc.) · Fountain Valley, California and 49 other locations · NCT04920617

• Comparing T Cell Depletion Methods for Blood Cancer Treatment

  This study is testing different ways to prevent complications after a stem cell transplant for blood cancer to see which method helps patients stay healthy and cancer-free longer.

  Recruiting at 17 sites Phase 2 University of Birmingham · Cardiff, Wales and 16 other locations · NCT04888741

• Combining post-transplant cyclophosphamide with uhCG/EGF for preventing Graft Versus Host Disease

  This study is testing if a new combination of medications can help prevent Graft Versus Host Disease in patients with blood cancers who are getting stem cell transplants from unrelated donors.

  Recruiting Phase 1 Henry Ford Health System · Detroit, Michigan · NCT04886726

• Treatment for Primary Mediastinal Large B-cell Lymphoma with Antibody Therapy and ImmunoChemotherapy

  This study is testing a new combination of antibody therapy and chemotherapy to see if it helps people with untreated primary mediastinal large B-cell lymphoma feel better and improve their quality of life.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT04745949

• Evaluating a new chemotherapy regimen for HER2-negative breast cancer before surgery

  This study is testing a new type of chemotherapy to see if it works better than standard treatment for women with HER2-negative breast cancer before they have surgery.

  Recruiting Phase 2/3 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT04576143

• Comparing two methods to prevent GVHD in leukemia patients after transplant

  This study is testing whether a new method using cyclophosphamide can better prevent graft-versus-host disease in leukemia patients after they receive a stem cell transplant compared to the usual treatment.

  Recruiting Phase 3 King Faisal Specialist Hospital & Research Center · Riyadh · NCT04314219

• Combination treatment for multiple myeloma patients with kidney issues

  This study is testing a new combination treatment for people with multiple myeloma and kidney problems to see if it helps them respond better to therapy before a stem cell transplant.

  Recruiting Phase 2 Medical College of Wisconsin · Milwaukee, Wisconsin · NCT04240054

• Using GM-CSF after transplant to improve recovery from blood cancers

  This study is testing if a drug called GM-CSF can help people recovering from blood cancers after a specific type of stem cell transplant to improve their blood cell counts and reduce infection risks.

  Recruiting Phase 2 Northside Hospital, Inc. · Atlanta, Georgia · NCT04237623

• Intensity Modulated Total Marrow Irradiation for Acute Leukemia and MDS

  This study is testing a new type of radiation treatment before a stem cell transplant to see if it helps people with acute leukemia or myelodysplastic syndromes do better.

  Recruiting Phase 2 University of Illinois Chicago · Chicago, Illinois · NCT04187105

• Comparing two treatment approaches for Waldenström's macroglobulinaemia

  This study is testing a new treatment without chemotherapy for people with Waldenström's macroglobulinaemia to see if it works better and is easier on the body than the standard treatment.

  Recruiting at 25 sites Phase 2/3 University College, London · Bath and 24 other locations · NCT04061512

• Using bendamustine with or without cyclophosphamide to prevent GVHD in stem cell transplant patients

  This study is testing whether using bendamustine alone or with cyclophosphamide can help prevent graft-versus-host disease in patients getting stem cell transplants for blood cancers.

  Recruiting Phase 1/2 M.D. Anderson Cancer Center · Houston, Texas · NCT04022239

• Treatment for chest wall breast cancer using pembrolizumab and cyclophosphamide

  This study is testing a combination of two medications, pembrolizumab and cyclophosphamide, to see if they can help people with breast cancer that has spread to the chest wall.

  Recruiting Phase 2 European Institute of Oncology · Milan · NCT03971045

• Strategies to reduce graft versus host disease in blood stem cell transplant patients with acute leukemia or MDS

  This study is testing two different treatment plans to see which one better helps prevent graft versus host disease in patients with acute leukemia or myelodysplastic syndrome after they receive a blood stem cell transplant.

  Recruiting at 3 sites Phase 2 Fred Hutchinson Cancer Center · Tampa, Florida and 2 other locations · NCT03970096

• HLA-Haploidentical Stem Cell Transplant with Cyclophosphamide and Bortezomib

  This study is testing a new stem cell transplant method for patients with blood cancers who don't have a matched donor, using special medications to help their bodies accept the transplant and recover better.

  Recruiting Phase 2 Henry Ford Health System · Detroit, Michigan · NCT03850366

• Cord blood transplantation with a specific conditioning regimen and post-transplant treatment

  This study is testing a new way to use cord blood for transplants to see if a specific treatment can help prevent complications and improve recovery for patients receiving the transplant.

  Recruiting Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Roma, RM · NCT03802773

• Examining factors that affect the effectiveness of post-transplant cyclophosphamide

  This study is trying to see how genetic factors and drug levels affect the success of a treatment called post-transplant cyclophosphamide in patients who have had a stem cell transplant.

  Recruiting Wake Forest University Health Sciences · Charlotte, North Carolina · NCT03555851

• Transplantation using family member stem cells for severe blood disorders

  This study is testing if using stem cells from family members can help people with severe blood disorders feel better and have better results than traditional bone marrow transplants.

  Recruiting Phase 2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT03520647

• Personalized vaccine for treating chronic lymphocytic leukemia

  This study is testing a new personalized cancer vaccine for people with chronic lymphocytic leukemia who haven't had treatment yet, to see how well it works and if it's safe.

  Recruiting Phase 1 Dana-Farber Cancer Institute · Boston, Massachusetts · NCT03219450

• Combination chemotherapy for relapsed or refractory acute lymphoblastic leukemia and related conditions

  This study is testing a new combination of chemotherapy drugs to see if it can help people with relapsed or hard-to-treat acute lymphoblastic leukemia and related blood cancers feel better and live longer.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT03136146

• Using Cyclophosphamide and Sirolimus to treat advanced thyroid cancer

  This study is testing if a combination of two medications, Cyclophosphamide and Sirolimus, can help people with advanced thyroid cancer that hasn't responded to other treatments.

  Recruiting Phase 2 University of Michigan Rogel Cancer Center · Ann Arbor, Michigan · NCT03099356

• Vaccine treatment for relapsed or refractory blood cancers

  This study is testing a new vaccine treatment for people with relapsed or hard-to-treat blood cancers to see if it can help them feel better and live longer.

  Recruiting at 2 sites Phase 1 Mayo Clinic · Scottsdale, Arizona and 1 other locations · NCT03017820

• Haploidentical bone marrow transplant for severe aplastic anemia

  This study is testing if a special type of bone marrow transplant from a mismatched donor can help people with severe aplastic anemia who don't have a matching donor.

  Recruiting at 2 sites Phase 2 Northside Hospital, Inc. · Atlanta, Georgia and 1 other locations · NCT02828592

• Transplant for Patients with Fanconi Anemia Using Adjusted Chemotherapy

  This study is testing a new way to use lower doses of chemotherapy before a stem cell transplant to see if it can safely help people with Fanconi anemia and serious blood disorders.

  Recruiting at 2 sites Phase 2 Children's Hospital Medical Center, Cincinnati · New York, New York and 2 other locations · NCT02143830

• Combination therapy with MM-398 liposome irinotecan and cyclophosphamide in children with solid tumors

  This study tests whether a higher dose of MM-398 (liposomal irinotecan) can be given safely when used with cyclophosphamide in children with recurring or treatment-refractory solid tumors.

  Recruiting at 5 sites Phase 1 South Plains Oncology Consortium · Cincinnati, Ohio and 4 other locations · NCT02013336

Quick answers

How many clinical trials of Cyclophosphamide are recruiting right now?

119, as of November 12, 2026. 2 of them were first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 30 countries. The most sites are in United States (59 trials), China (30 trials), France (10 trials), Italy (8 trials), Russia (7 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 59, Phase 1/2: 17, Phase 1: 16, Phase 3: 12. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →